O023 Quality of Life in Central Disorders of Hypersomnolence

Abstract

Abstract Background Whilst sleep disorders are common, with up to 5.8% of Australian adults experiencing excessive daytime somnolence due to a sleep disorder, there is a relative paucity of quality-of-life data in those with central disorders of hypersomnolence. The available evidence suggests a significant impact attributable to these disorders, though it is also noted that much of this data was obtained through patient associations as opposed to sleep medicine clinics with potentially more security of diagnosis. Methods A retrospective, single-centre review will be undertaken of patients seen as new cases in the sleep clinic between January 2013 and December 2022 with a diagnosis of a central disorder of hypersomnolence. Quality of life at baseline will be assessed using metrics collected as standard-of-care, including the Epworth Sleepiness Scale, Short-Form 36, FOSQ, and PSQI. Demographics, comorbidity, baseline pharmacotherapy will also be analysed. Progress to date Planning in conjunction with co-investigators and key stakeholders has been undertaken, and a complete protocol has been drafted and submitted for ethics committee approval. Data collection is anticipated to commence and be complete by end of July 2023. Intended outcome and impact It is hypothesised that baseline quality of life in these patients will be poorer than in the general population. This study will improve upon the volume and quality of existing data, and serve to assist in planning for a potential subsequent investigation into the impact of cognitive behavioural therapy for hypersomnia.